{"protocolSection": {"identificationModule": {"nctId": "NCT03548584", "orgStudyIdInfo": {"id": "331-14-213"}, "organization": {"fullName": "Otsuka Pharmaceutical Development & Commercialization, Inc.", "class": "INDUSTRY"}, "briefTitle": "A Trial to Evaluate the Safety, Efficacy, and Tolerability of Brexpiprazole in Treating Agitation Associated With Dementia of the Alzheimer's Type", "officialTitle": "A Phase 3, 12-Week, Multicenter, Randomized, Double-blind, Placebo-controlled, 2-Arm, Fixed-dose Trial to Evaluate the Efficacy, Safety, and Tolerability of Brexpiprazole (OPC-34712) in the Treatment of Subjects With Agitation Associated With Dementia of the Alzheimer's Type"}, "statusModule": {"statusVerifiedDate": "2023-09", "overallStatus": "COMPLETED", "expandedAccessInfo": {"hasExpandedAccess": false}, "startDateStruct": {"date": "2018-05-16", "type": "ACTUAL"}, "primaryCompletionDateStruct": {"date": "2022-05-23", "type": "ACTUAL"}, "completionDateStruct": {"date": "2022-06-01", "type": "ACTUAL"}, "studyFirstSubmitDate": "2018-05-07", "studyFirstSubmitQcDate": "2018-06-05", "studyFirstPostDateStruct": {"date": "2018-06-07", "type": "ACTUAL"}, "resultsFirstSubmitDate": "2023-05-31", "resultsFirstSubmitQcDate": "2023-09-14", "resultsFirstPostDateStruct": {"date": "2023-09-18", "type": "ACTUAL"}, "lastUpdateSubmitDate": "2023-09-14", "lastUpdatePostDateStruct": {"date": "2023-09-18", "type": "ACTUAL"}}, "sponsorCollaboratorsModule": {"responsibleParty": {"type": "SPONSOR"}, "leadSponsor": {"name": "Otsuka Pharmaceutical Development & Commercialization, Inc.", "class": "INDUSTRY"}, "collaborators": [{"name": "H. Lundbeck A/S", "class": "INDUSTRY"}]}, "oversightModule": {"isFdaRegulatedDrug": true, "isFdaRegulatedDevice": false}, "descriptionModule": {"briefSummary": "This study compares the efficacy of 2 doses of brexpiprazole with placebo in participants with agitation associated with dementia of the Alzheimer's type.", "detailedDescription": "This is a phase 3, 12-week, multicenter, randomized, double-blind, placebo-controlled, fixed-dose trial designed to assess the efficacy, safety, and tolerability of brexpiprazole compared with placebo. The trial consists of a 12-week double-blind treatment period with a 30 day follow-up. The trial population will include male and female participants between 55 and 90 years of age (inclusive) with a diagnosis of probable Alzheimer's disease, who are residing either in an institutionalized setting or in a non-institutionalized setting where the participant is not living alone. This trial will analyze data gathered from approximately 330 participants at multiple countries. Participants may also be eligible to enter an active treatment extension trial."}, "conditionsModule": {"conditions": ["Agitation Associated With Alzheimer's Dementia", "Alzheimer Dementia"], "keywords": ["Agitation"]}, "designModule": {"studyType": "INTERVENTIONAL", "phases": ["PHASE3"], "designInfo": {"allocation": "RANDOMIZED", "interventionModel": "PARALLEL", "primaryPurpose": "TREATMENT", "maskingInfo": {"masking": "QUADRUPLE", "whoMasked": ["PARTICIPANT", "CARE_PROVIDER", "INVESTIGATOR", "OUTCOMES_ASSESSOR"]}}, "enrollmentInfo": {"count": 345, "type": "ACTUAL"}}, "armsInterventionsModule": {"armGroups": [{"label": "Brexpiprazole 2 mg", "type": "EXPERIMENTAL", "description": "Participants followed a titration schedule, to gradually increase their dose from 0.5 milligrams per day (mg/day) in the starting to 2 mg/day from Day 15. Participants continued to receive brexpiprazole 2 milligrams (mg), once daily until Week 12.", "interventionNames": ["Drug: Brexpiprazole"]}, {"label": "Brexpiprazole 3 mg", "type": "EXPERIMENTAL", "description": "Participants followed a titration schedule, to gradually increase their dose from 0.5 mg/day in the starting to 3 mg/day from Day 29. Participants continued to receive brexpiprazole 3 mg, once daily until Week 12.", "interventionNames": ["Drug: Brexpiprazole"]}, {"label": "Placebo", "type": "PLACEBO_COMPARATOR", "description": "Participants received matching placebo, once daily for 12 weeks.", "interventionNames": ["Other: Placebo"]}], "interventions": [{"type": "DRUG", "name": "Brexpiprazole", "description": "Oral tablets", "armGroupLabels": ["Brexpiprazole 2 mg", "Brexpiprazole 3 mg"], "otherNames": ["OPC-34712"]}, {"type": "OTHER", "name": "Placebo", "description": "Oral tablets", "armGroupLabels": ["Placebo"]}]}, "outcomesModule": {"primaryOutcomes": [{"measure": "Change From Baseline to Week 12 in the CMAI Total Score", "description": "The CMAI score is used to assess the frequency of manifestations of agitated behaviors in participants. The CMAI consists of 29 agitated behaviors that are rated on a 7-point scale of frequency across four subscales of aggressive behavior, physically nonaggressive behavior, verbally agitated behavior and hiding and hoarding as: 1=never; 2=less than once a week; 3=once or twice a week; 4=several times a week; 5=once or twice a day; 6=several times a day; 7=several times an hour. The CMAI total score ranges from 29 to 203. Higher scores indicate worsening of the condition. A negative change from baseline indicates improvement. Mixed model repeated measures (MMRM) was used for the analysis. As prespecified in the statistical analysis plan (SAP), data for this outcome measure was analyzed and reported in a combined way for brexpiprazole 2 and 3 mg.", "timeFrame": "Baseline and Week 12"}], "secondaryOutcomes": [{"measure": "Change From Baseline to Week 12 in the Clinical Global Impression Severity of Illness (CGI-S) Score, as Related to Agitation", "description": "CGI-S was used to rate the severity of agitation. The score ranges from 0 to 7 with response choices as, 0=not assessed; 1=normal, not at all ill; 2=borderline mentally ill; 3=mildly ill; 4=moderately ill; 5=markedly ill; 6=severely ill; and 7=among the most extremely ill participants. The higher the value, the more severe the agitation. A negative change from baseline indicates improvement. MMRM was used for the analysis. As prespecified in the SAP, data for this outcome measure was analyzed and reported in a combined way for brexpiprazole 2 and 3 mg.", "timeFrame": "Baseline and Week 12"}, {"measure": "Change From Baseline to Week 12 in CMAI Subscale Scores", "description": "The CMAI score is used to assess the frequency of manifestations of agitated behaviors in participants. It consists of 29 agitated behaviors that are rated on a 7-point scale of frequency across four subscales of aggressive behavior, physically nonaggressive behavior, verbally agitated behavior and hiding and hoarding, as: 1=never; 2=less than once a week; 3=once or twice a week; 4=several times a week; 5=once or twice a day; 6=several times a day; 7=several times an hour. The four subscales include 12, 6, 4, and 2 items, respectively. The score of the subscale is the sum of the individual items included in the subscale, so the score range for each of the 4 subscales is 0 to 84, 0 to 42, 0 to 28, and 0 to 14, respectively. Higher scores indicate worsening of the condition. A negative change from baseline=improvement. MMRM was used for the analysis. As prespecified in the SAP, data for this outcome measure was analyzed and reported in a combined way for brexpiprazole 2 and 3 mg.", "timeFrame": "Baseline and Week 12"}, {"measure": "Change From Baseline in CMAI Total Score for Each Trial Visit During the Double-blind Treatment Period", "description": "The CMAI score is used to assess the frequency of manifestations of agitated behaviors in participants. The CMAI consists of 29 agitated behaviors that are rated on a 7-point scale of frequency across four subscales of aggressive behavior, physically nonaggressive behavior, verbally agitated behavior and hiding and hoarding as: 1=never; 2=less than once a week; 3=once or twice a week; 4=several times a week; 5=once or twice a day; 6=several times a day; 7=several times an hour. The CMAI total score ranges from 29 to 203. Higher scores indicate worsening of the condition. A negative change from baseline indicates improvement. MMRM was used for the analysis. As prespecified in the SAP, data for this outcome measure was analyzed and reported in a combined way for brexpiprazole 2 and 3 mg.", "timeFrame": "Baseline, Weeks 2, 4, 6, 8, 10, and 12"}, {"measure": "Change From Baseline in CGI-S for Each Trial Visit During the Double-Blind Treatment Period", "description": "CGI-S was used to rate the severity of agitation. The score ranges from 0 to 7 with response choices as, 0=not assessed; 1=normal, not at all ill; 2=borderline mentally ill; 3=mildly ill; 4=moderately ill; 5=markedly ill; 6=severely ill; and 7=among the most extremely ill participants. The higher the value, the more severe the agitation. A negative change from baseline indicates improvement. MMRM was used for the analysis. As prespecified in the SAP, data for this outcome measure was analyzed and reported in a combined way for brexpiprazole 2 and 3 mg.", "timeFrame": "Baseline, Weeks 2, 4, 6, 8, 10, and 12"}, {"measure": "Clinical Global Impressions-Improvement (CGI-I) Score at Each Trial Visit During the Double-Blind Treatment Period", "description": "CGI-I is a 7-point scale that requires the clinician to assess whether a participant's condition has improved or worsened relative to a baseline state at the beginning of the intervention. This was rated as: 1=very much improved; 2=much improved; 3=minimally improved; 4=no change; 5=minimally worse; 6=much worse; or 7=very much worse. Higher scores indicate worse condition. As prespecified in the SAP, data for this outcome measure was analyzed and reported in a combined way for brexpiprazole 2 and 3 mg.", "timeFrame": "Baseline, Weeks 2, 4, 6, 8, 10, and 12"}, {"measure": "CMAI Response Rate Assessed as Percentage of Participants With CMAI Response at Every Scheduled Trial Visit in the Double-Blind Treatment Period", "description": "The CMAI assesses frequency of agitated behaviors in elderly persons. The scale consists of 29 agitated behaviors that are further categorized into distinct agitation syndromes, also known as CMAI factors of agitation. Each of the agitated behaviors are scored 1 (never) to 7 (several times an hours), with the total scale score ranging from 29 to 203. Higher score indicates greater frequency of agitated behavior. As prespecified in the SAP, data for this outcome measure was analyzed and reported in a combined way for brexpiprazole 2 and 3 mg.", "timeFrame": "Weeks 2, 4, 6, 8, 10, and 12"}, {"measure": "CMAI Response Rate Assessed as Percentage of Participants With CMAI Response Based on Improvement From Baseline in Agitation Status at Every Scheduled Trial Visit in the Double-Blind Treatment Period", "description": "The CMAI assesses frequency of agitated behaviors in elderly persons. The scale consists of 29 agitated behaviors that are further categorized into distinct agitation syndromes, also known as CMAI factors of agitation. Each of the agitated behaviors are scored 1 (never) to 7 (several times an hours), with the total scale score ranging from 29 to 203. Higher score indicates greater frequency of agitated behavior. As prespecified in the SAP, data for this outcome measure was analyzed and reported in a combined way for brexpiprazole 2 and 3 mg.", "timeFrame": "Baseline, Weeks 2, 4, 6, 8, 10, and 12"}, {"measure": "CGI-I Response Rate Assessed as Percentage of Participants With CGI-I Response at Every Scheduled Trial Visit in the Double-Blind Treatment Period", "description": "CGI-I is a 7-point scale that requires the clinician to assess whether a participant's condition has improved or worsened relative to a baseline state at the beginning of the intervention. This was rated as: 1=very much improved; 2=much improved; 3=minimally improved; 4=no change; 5=minimally worse; 6=much worse; or 7=very much worse. Higher scores indicate worse condition. As prespecified in the SAP, data for this outcome measure was analyzed and reported in a combined way for brexpiprazole 2 and 3 mg.", "timeFrame": "Baseline, Weeks 2, 4, 6, 8, 10, and 12"}]}, "eligibilityModule": {"eligibilityCriteria": "Inclusion Criteria:\n\n* Participants with a diagnosis of probable Alzheimer's disease.\n* Participants with a diagnosis of agitation\n* Participants with a MMSE score of 5 to 22, inclusive, at screening and baseline visits.\n* Participants with a previous MRI or CT scan of the brain, that was performed after the onset of symptoms of dementia, with findings consistent with a diagnosis of Alzheimer's disease.\n* Participants who are residing at their current location for at least 28 days before screening and are expected to remain at the same location for the duration of the trial.\n* Institutionalized participants with an identified caregiver who has sufficient contact (minimum of 2 hours per day for 4 days per week) to describe the participant's symptoms and has direct observation of the participant's behavior. Non-institutionalized participants may not be living alone and must have an identified caregiver who has sufficient contact (minimum of 2 hours per day for 4 days per week) to describe the participant's symptoms and has direct observation of the participant's behavior.\n* Participants with onset of symptoms of agitation at least 2 weeks prior to screening visit.\n* Participants will and able to discontinue all prohibited concomitant medications to meet protocol required washouts prior to and during the trial period.\n\nExclusion Criteria:\n\n* Participants with dementia or other memory impairment not due to Alzheimer's disease.\n* Participants with a history of stroke, well-documented transient ischemic attack, or pulmonary or cerebral embolism.\n* Participants who had an insufficient response, based on the investigator's judgment, to 2 or more previous antipsychotic medications.\n* Participants who have been diagnosed with an Axis I disorder.\n* Participants who currently have clinically significant neurological, hepatic, renal, metabolic, hematological, immunological, cardiovascular, pulmonary, gastrointestinal, or psychiatric disorders.\n* Participants with uncontrolled hypertension or symptomatic hypotension, or orthostatic hypotension.\n* Participants with diabetes mellitus (insulin-dependent and non-insulin-dependent) may be eligible for the trial if their condition is stable and well-controlled.", "healthyVolunteers": false, "sex": "ALL", "minimumAge": "55 Years", "maximumAge": "90 Years", "stdAges": ["ADULT", "OLDER_ADULT"]}, "contactsLocationsModule": {"locations": [{"facility": "For additional information regarding sites, contact 844-687-8522", "city": "Los Angeles", "state": "California", "zip": "90036", "country": "United States", "geoPoint": {"lat": 34.05223, "lon": -118.24368}}]}, "ipdSharingStatementModule": {"ipdSharing": "YES", "description": "Anonymized Individual participant data (IPD) that underlie the results of this study will be shared with researchers to achieve aims pre-specified in a methodologically sound research proposal. Small studies with less than 25 participants are excluded from data sharing.", "infoTypes": ["STUDY_PROTOCOL", "SAP", "CSR"], "timeFrame": "Data will be available after marketing approval in global markets, or beginning 1-3 years following article publication. There is no end date to the availability of the data.", "accessCriteria": "Otsuka will share data on the Vivli data sharing platform which can be found here: https://vivli.org/ourmember/Otsuka/", "url": "https://clinical-trials.otsuka.com"}}, "resultsSection": {"participantFlowModule": {"recruitmentDetails": "A total of 345 participants were randomized, and participated in the study from 16 May 2018 to 1 June 2022.", "groups": [{"id": "FG000", "title": "Brexpiprazole 2 mg", "description": "Participants followed a titration schedule, to gradually increase their dose from 0.5 milligrams per day (mg/day) in the starting to 2 mg/day from Day 15. Participants continued to receive brexpiprazole 2 milligrams (mg), once daily until Week 12."}, {"id": "FG001", "title": "Brexpiprazole 3 mg", "description": "Participants followed a titration schedule, to gradually increase their dose from 0.5 mg/day in the starting to 3 mg/day from Day 29. Participants continued to receive brexpiprazole 3 mg, once daily until Week 12."}, {"id": "FG002", "title": "Placebo", "description": "Participants received matching placebo, once daily for 12 weeks."}], "periods": [{"title": "Overall Study", "milestones": [{"type": "STARTED", "achievements": [{"groupId": "FG000", "numSubjects": "75"}, {"groupId": "FG001", "numSubjects": "153"}, {"groupId": "FG002", "numSubjects": "117"}]}, {"type": "Intent-to-treat Population", "comment": "Intent-to-treat (ITT) Population consisted of all participants in the randomized sample, who took at least 1 dose of investigational medical product (IMP) and had a baseline and at least one post-baseline evaluation for the Cohen-Mansfield Agitation Inventory (CMAI) total score.", "achievements": [{"groupId": "FG000", "numSubjects": "73"}, {"groupId": "FG001", "numSubjects": "153"}, {"groupId": "FG002", "numSubjects": "116"}]}, {"type": "COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "68"}, {"groupId": "FG001", "numSubjects": "130"}, {"groupId": "FG002", "numSubjects": "104"}]}, {"type": "NOT COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "7"}, {"groupId": "FG001", "numSubjects": "23"}, {"groupId": "FG002", "numSubjects": "13"}]}], "dropWithdraws": [{"type": "Lost to Follow-up", "reasons": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "0"}, {"groupId": "FG002", "numSubjects": "1"}]}, {"type": "Adverse Event", "reasons": [{"groupId": "FG000", "numSubjects": "1"}, {"groupId": "FG001", "numSubjects": "11"}, {"groupId": "FG002", "numSubjects": "5"}]}, {"type": "Site Terminated by Sponsor", "reasons": [{"groupId": "FG000", "numSubjects": "1"}, {"groupId": "FG001", "numSubjects": "3"}, {"groupId": "FG002", "numSubjects": "2"}]}, {"type": "Subject Withdrew Consent to Participate", "reasons": [{"groupId": "FG000", "numSubjects": "5"}, {"groupId": "FG001", "numSubjects": "5"}, {"groupId": "FG002", "numSubjects": "3"}]}, {"type": "Lack of Efficacy", "reasons": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "1"}, {"groupId": "FG002", "numSubjects": "0"}]}, {"type": "Non-compliance with Study Drug", "reasons": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "1"}, {"groupId": "FG002", "numSubjects": "0"}]}, {"type": "Reason not Specified (Not Related to Coronavirus Disease 2019 [COVID-19])", "reasons": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "2"}, {"groupId": "FG002", "numSubjects": "2"}]}]}]}, "baselineCharacteristicsModule": {"populationDescription": "Randomized Sample consisted of all participants who were randomized into this trial.", "groups": [{"id": "BG000", "title": "Brexpiprazole 2 mg", "description": "Participants followed a titration schedule, to gradually increase their dose from 0.5 mg/day in the starting to 2 mg/day from Day 15. Participants continued to receive brexpiprazole 2 mg, once daily until Week 12."}, {"id": "BG001", "title": "Brexpiprazole 3 mg", "description": "Participants followed a titration schedule, to gradually increase their dose from 0.5 mg/day in the starting to 3 mg/day from Day 29. Participants continued to receive brexpiprazole 3 mg, once daily until Week 12."}, {"id": "BG002", "title": "Placebo", "description": "Participants received matching placebo, once daily for 12 weeks."}, {"id": "BG003", "title": "Total", "description": "Total of all reporting groups"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "75"}, {"groupId": "BG001", "value": "153"}, {"groupId": "BG002", "value": "117"}, {"groupId": "BG003", "value": "345"}]}], "measures": [{"title": "Age, Continuous", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "years", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "74.3", "spread": "7.3"}, {"groupId": "BG001", "value": "74.6", "spread": "8.0"}, {"groupId": "BG002", "value": "73.0", "spread": "7.0"}, {"groupId": "BG003", "value": "74.0", "spread": "7.5"}]}]}]}, {"title": "Sex: Female, Male", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"title": "Female", "measurements": [{"groupId": "BG000", "value": "43"}, {"groupId": "BG001", "value": "92"}, {"groupId": "BG002", "value": "60"}, {"groupId": "BG003", "value": "195"}]}, {"title": "Male", "measurements": [{"groupId": "BG000", "value": "32"}, {"groupId": "BG001", "value": "61"}, {"groupId": "BG002", "value": "57"}, {"groupId": "BG003", "value": "150"}]}]}]}, {"title": "Ethnicity (NIH/OMB)", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"title": "Hispanic or Latino", "measurements": [{"groupId": "BG000", "value": "25"}, {"groupId": "BG001", "value": "46"}, {"groupId": "BG002", "value": "37"}, {"groupId": "BG003", "value": "108"}]}, {"title": "Not Hispanic or Latino", "measurements": [{"groupId": "BG000", "value": "50"}, {"groupId": "BG001", "value": "107"}, {"groupId": "BG002", "value": "80"}, {"groupId": "BG003", "value": "237"}]}, {"title": "Unknown or Not Reported", "measurements": [{"groupId": "BG000", "value": "0"}, {"groupId": "BG001", "value": "0"}, {"groupId": "BG002", "value": "0"}, {"groupId": "BG003", "value": "0"}]}]}]}, {"title": "Race (NIH/OMB)", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"title": "American Indian or Alaska Native", "measurements": [{"groupId": "BG000", "value": "0"}, {"groupId": "BG001", "value": "0"}, {"groupId": "BG002", "value": "0"}, {"groupId": "BG003", "value": "0"}]}, {"title": "Asian", "measurements": [{"groupId": "BG000", "value": "0"}, {"groupId": "BG001", "value": "3"}, {"groupId": "BG002", "value": "1"}, {"groupId": "BG003", "value": "4"}]}, {"title": "Native Hawaiian or Other Pacific Islander", "measurements": [{"groupId": "BG000", "value": "0"}, {"groupId": "BG001", "value": "0"}, {"groupId": "BG002", "value": "0"}, {"groupId": "BG003", "value": "0"}]}, {"title": "Black or African American", "measurements": [{"groupId": "BG000", "value": "5"}, {"groupId": "BG001", "value": "6"}, {"groupId": "BG002", "value": "1"}, {"groupId": "BG003", "value": "12"}]}, {"title": "White", "measurements": [{"groupId": "BG000", "value": "70"}, {"groupId": "BG001", "value": "144"}, {"groupId": "BG002", "value": "115"}, {"groupId": "BG003", "value": "329"}]}, {"title": "More than one race", "measurements": [{"groupId": "BG000", "value": "0"}, {"groupId": "BG001", "value": "0"}, {"groupId": "BG002", "value": "0"}, {"groupId": "BG003", "value": "0"}]}, {"title": "Unknown or Not Reported", "measurements": [{"groupId": "BG000", "value": "0"}, {"groupId": "BG001", "value": "0"}, {"groupId": "BG002", "value": "0"}, {"groupId": "BG003", "value": "0"}]}]}]}, {"title": "Cohen-Mansfield Agitation Inventory (CMAI) Total Score", "description": "The CMAI assesses frequency of agitated behaviors in elderly persons. The scale consists of 29 agitated behaviors that are further categorized into distinct agitation syndromes, also known as CMAI factors of agitation. Each of the agitated behaviors are scored 1 (never) to 7 (several times an hours), with the total scale score ranging from 29 to 203. Higher score indicates greater frequency of agitated behavior.", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "score on a scale", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "78.6", "spread": "15.5"}, {"groupId": "BG001", "value": "81.2", "spread": "17.2"}, {"groupId": "BG002", "value": "79.4", "spread": "17.6"}, {"groupId": "BG003", "value": "80", "spread": "17"}]}]}]}]}, "outcomeMeasuresModule": {"outcomeMeasures": [{"type": "PRIMARY", "title": "Change From Baseline to Week 12 in the CMAI Total Score", "description": "The CMAI score is used to assess the frequency of manifestations of agitated behaviors in participants. The CMAI consists of 29 agitated behaviors that are rated on a 7-point scale of frequency across four subscales of aggressive behavior, physically nonaggressive behavior, verbally agitated behavior and hiding and hoarding as: 1=never; 2=less than once a week; 3=once or twice a week; 4=several times a week; 5=once or twice a day; 6=several times a day; 7=several times an hour. The CMAI total score ranges from 29 to 203. Higher scores indicate worsening of the condition. A negative change from baseline indicates improvement. Mixed model repeated measures (MMRM) was used for the analysis. As prespecified in the statistical analysis plan (SAP), data for this outcome measure was analyzed and reported in a combined way for brexpiprazole 2 and 3 mg.", "populationDescription": "The ITT Population consisted of all participants in the randomized sample, who took at least 1 dose of IMP and had a baseline and at least one post-baseline evaluation for the CMAI total score. Overall number analyzed is the number of participants with data available for analyses.", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "score on a scale", "timeFrame": "Baseline and Week 12", "groups": [{"id": "OG000", "title": "Brexpiprazole 2 and 3 mg", "description": "Participants followed a titration schedule, to gradually increase their dose from 0.5 mg/day in the starting to 2 mg/day from Day 15 or from 0.5 mg/day in the starting to 3 mg/day from Day 29.\n\nParticipants continued to receive brexpiprazole 2 or 3 mg, once daily until Week 12."}, {"id": "OG001", "title": "Placebo", "description": "Participants received matching placebo, once daily for 12 weeks."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "225"}, {"groupId": "OG001", "value": "116"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-22.6", "spread": "1.08"}, {"groupId": "OG001", "value": "-17.3", "spread": "1.44"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "nonInferiorityType": "SUPERIORITY", "pValue": "0.0026", "pValueComment": "MMRM method with model terms of treatment, trial site, visit, treatment-by-visit and baseline-by-visit interaction were used for analysis.", "statisticalMethod": "MMRM", "paramType": "LS Mean Difference", "paramValue": "-5.32", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-8.77", "ciUpperLimit": "-1.87"}]}, {"type": "SECONDARY", "title": "Change From Baseline to Week 12 in the Clinical Global Impression Severity of Illness (CGI-S) Score, as Related to Agitation", "description": "CGI-S was used to rate the severity of agitation. The score ranges from 0 to 7 with response choices as, 0=not assessed; 1=normal, not at all ill; 2=borderline mentally ill; 3=mildly ill; 4=moderately ill; 5=markedly ill; 6=severely ill; and 7=among the most extremely ill participants. The higher the value, the more severe the agitation. A negative change from baseline indicates improvement. MMRM was used for the analysis. As prespecified in the SAP, data for this outcome measure was analyzed and reported in a combined way for brexpiprazole 2 and 3 mg.", "populationDescription": "The ITT Population consisted of all participants in the randomized sample, who took at least 1 dose of IMP and had a baseline and at least one post-baseline evaluation for the CMAI total score. Overall number analyzed is the number of participants with data available for analyses.", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "score on a scale", "timeFrame": "Baseline and Week 12", "groups": [{"id": "OG000", "title": "Brexpiprazole 2 and 3 mg", "description": "Participants followed a titration schedule, to gradually increase their dose from 0.5 mg/day in the starting to 2 mg/day from Day 15 or from 0.5 mg/day in the starting to 3 mg/day from Day 29.\n\nParticipants continued to receive brexpiprazole 2 or 3 mg, once daily until Week 12."}, {"id": "OG001", "title": "Placebo", "description": "Participants received matching placebo, once daily for 12 weeks."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "225"}, {"groupId": "OG001", "value": "116"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-1.20", "spread": "0.06"}, {"groupId": "OG001", "value": "-0.93", "spread": "0.08"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "nonInferiorityType": "SUPERIORITY", "pValue": "0.0078", "pValueComment": "MMRM method with model terms of treatment, trial site, visit, treatment-by-visit and baseline-by-visit interaction were used for analysis.", "statisticalMethod": "MMRM", "paramType": "LS Mean Difference", "paramValue": "-0.27", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-0.47", "ciUpperLimit": "-0.07"}]}, {"type": "SECONDARY", "title": "Change From Baseline to Week 12 in CMAI Subscale Scores", "description": "The CMAI score is used to assess the frequency of manifestations of agitated behaviors in participants. It consists of 29 agitated behaviors that are rated on a 7-point scale of frequency across four subscales of aggressive behavior, physically nonaggressive behavior, verbally agitated behavior and hiding and hoarding, as: 1=never; 2=less than once a week; 3=once or twice a week; 4=several times a week; 5=once or twice a day; 6=several times a day; 7=several times an hour. The four subscales include 12, 6, 4, and 2 items, respectively. The score of the subscale is the sum of the individual items included in the subscale, so the score range for each of the 4 subscales is 0 to 84, 0 to 42, 0 to 28, and 0 to 14, respectively. Higher scores indicate worsening of the condition. A negative change from baseline=improvement. MMRM was used for the analysis. As prespecified in the SAP, data for this outcome measure was analyzed and reported in a combined way for brexpiprazole 2 and 3 mg.", "populationDescription": "The ITT Population consisted of all participants in the randomized sample, who took at least 1 dose of IMP and had a baseline and at least one post-baseline evaluation for the CMAI total score. Overall number analyzed is the number of participants with data available for analyses.", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "score on a scale", "timeFrame": "Baseline and Week 12", "groups": [{"id": "OG000", "title": "Brexpiprazole 2 and 3 mg", "description": "Participants followed a titration schedule, to gradually increase their dose from 0.5 mg/day in the starting to 2 mg/day from Day 15 or from 0.5 mg/day in the starting to 3 mg/day from Day 29.\n\nParticipants continued to receive brexpiprazole 2 or 3 mg, once daily until Week 12."}, {"id": "OG001", "title": "Placebo", "description": "Participants received matching placebo, once daily for 12 weeks."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "225"}, {"groupId": "OG001", "value": "116"}]}], "classes": [{"title": "Aggressive Behavior", "categories": [{"measurements": [{"groupId": "OG000", "value": "-9.09", "spread": "0.42"}, {"groupId": "OG001", "value": "-7.13", "spread": "0.56"}]}]}, {"title": "Physically Nonaggressive Behavior", "categories": [{"measurements": [{"groupId": "OG000", "value": "-6.45", "spread": "0.40"}, {"groupId": "OG001", "value": "-5.04", "spread": "0.53"}]}]}, {"title": "Verbally Agitated Behavior", "categories": [{"measurements": [{"groupId": "OG000", "value": "-4.39", "spread": "0.31"}, {"groupId": "OG001", "value": "-3.14", "spread": "0.40"}]}]}, {"title": "Hiding and Hoarding", "categories": [{"measurements": [{"groupId": "OG000", "value": "-1.50", "spread": "0.17"}, {"groupId": "OG001", "value": "-1.14", "spread": "0.23"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "groupDescription": "Aggressive Behavior", "nonInferiorityType": "SUPERIORITY", "pValue": "0.0040", "pValueComment": "MMRM method with model terms of treatment, trial site, visit, treatment-by-visit and baseline-by-visit interaction were used for analysis.", "statisticalMethod": "MMRM", "paramType": "LS Mean Difference", "paramValue": "-1.95", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-3.28", "ciUpperLimit": "-0.63"}, {"groupIds": ["OG000", "OG001"], "groupDescription": "Physically Nonaggressive Behavior", "nonInferiorityType": "SUPERIORITY", "pValue": "0.0296", "pValueComment": "MMRM method with model terms of treatment, trial site, visit, treatment-by-visit and baseline-by-visit interaction were used for analysis.", "statisticalMethod": "MMRM", "paramType": "LS Mean Difference", "paramValue": "-1.41", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-2.68", "ciUpperLimit": "-0.14"}, {"groupIds": ["OG000", "OG001"], "groupDescription": "Verbally Agitated Behavior", "nonInferiorityType": "SUPERIORITY", "pValue": "0.0113", "pValueComment": "MMRM method with model terms of treatment, trial site, visit, treatment-by-visit and baseline-by-visit interaction were used for analysis.", "statisticalMethod": "MMRM", "paramType": "LS Mean Difference", "paramValue": "-1.24", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-2.21", "ciUpperLimit": "-0.28"}, {"groupIds": ["OG000", "OG001"], "groupDescription": "Hiding and Hoarding", "nonInferiorityType": "SUPERIORITY", "pValue": "0.1941", "pValueComment": "MMRM method with model terms of treatment, trial site, visit, treatment-by-visit and baseline-by-visit interaction were used for analysis.", "statisticalMethod": "MMRM", "paramType": "LS Mean Difference", "paramValue": "-0.36", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-0.90", "ciUpperLimit": "0.18"}]}, {"type": "SECONDARY", "title": "Change From Baseline in CMAI Total Score for Each Trial Visit During the Double-blind Treatment Period", "description": "The CMAI score is used to assess the frequency of manifestations of agitated behaviors in participants. The CMAI consists of 29 agitated behaviors that are rated on a 7-point scale of frequency across four subscales of aggressive behavior, physically nonaggressive behavior, verbally agitated behavior and hiding and hoarding as: 1=never; 2=less than once a week; 3=once or twice a week; 4=several times a week; 5=once or twice a day; 6=several times a day; 7=several times an hour. The CMAI total score ranges from 29 to 203. Higher scores indicate worsening of the condition. A negative change from baseline indicates improvement. MMRM was used for the analysis. As prespecified in the SAP, data for this outcome measure was analyzed and reported in a combined way for brexpiprazole 2 and 3 mg.", "populationDescription": "The ITT Population consisted of all participants in the randomized sample, who took at least 1 dose of IMP and had a baseline and at least one post-baseline evaluation for the CMAI total score. Overall number analyzed is the number of participants with data available for analyses.", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "score on a scale", "timeFrame": "Baseline, Weeks 2, 4, 6, 8, 10, and 12", "groups": [{"id": "OG000", "title": "Brexpiprazole 2 and 3 mg", "description": "Participants followed a titration schedule, to gradually increase their dose from 0.5 mg/day in the starting to 2 mg/day from Day 15 or from 0.5 mg/day in the starting to 3 mg/day from Day 29.\n\nParticipants continued to receive brexpiprazole 2 or 3 mg, once daily until Week 12."}, {"id": "OG001", "title": "Placebo", "description": "Participants received matching placebo, once daily for 12 weeks."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "225"}, {"groupId": "OG001", "value": "116"}]}], "classes": [{"title": "Change From Baseline at Week 2", "categories": [{"measurements": [{"groupId": "OG000", "value": "-5.76", "spread": "0.71"}, {"groupId": "OG001", "value": "-6.61", "spread": "0.90"}]}]}, {"title": "Change From Baseline at Week 4", "categories": [{"measurements": [{"groupId": "OG000", "value": "-12.1", "spread": "0.82"}, {"groupId": "OG001", "value": "-11.0", "spread": "1.06"}]}]}, {"title": "Change From Baseline at Week 6", "categories": [{"measurements": [{"groupId": "OG000", "value": "-16.2", "spread": "0.91"}, {"groupId": "OG001", "value": "-13.9", "spread": "1.19"}]}]}, {"title": "Change From Baseline at Week 8", "categories": [{"measurements": [{"groupId": "OG000", "value": "-19.4", "spread": "0.96"}, {"groupId": "OG001", "value": "-14.4", "spread": "1.28"}]}]}, {"title": "Change From Baseline at Week 10", "categories": [{"measurements": [{"groupId": "OG000", "value": "-22.2", "spread": "0.97"}, {"groupId": "OG001", "value": "-15.7", "spread": "1.29"}]}]}, {"title": "Change From Baseline at Week 12", "categories": [{"measurements": [{"groupId": "OG000", "value": "-22.6", "spread": "1.08"}, {"groupId": "OG001", "value": "-17.3", "spread": "1.44"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "groupDescription": "Change From Baseline at Week 2", "nonInferiorityType": "SUPERIORITY", "pValue": "0.4242", "pValueComment": "MMRM method with model terms of treatment, trial site, visit, treatment-by-visit and baseline-by-visit interaction were used for analysis.", "statisticalMethod": "MMRM", "paramType": "LS Mean Difference", "paramValue": "0.85", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-1.24", "ciUpperLimit": "2.93"}, {"groupIds": ["OG000", "OG001"], "groupDescription": "Change From Baseline at Week 4", "nonInferiorityType": "SUPERIORITY", "pValue": "0.3665", "pValueComment": "MMRM method with model terms of treatment, trial site, visit, treatment-by-visit and baseline-by-visit interaction were used for analysis.", "statisticalMethod": "MMRM", "paramType": "LS Mean Difference", "paramValue": "-1.14", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-3.63", "ciUpperLimit": "1.34"}, {"groupIds": ["OG000", "OG001"], "groupDescription": "Change from Baseline at Week 6", "nonInferiorityType": "SUPERIORITY", "pValue": "0.1065", "pValueComment": "MMRM method with model terms of treatment, trial site, visit, treatment-by-visit and baseline-by-visit interaction were used for analysis.", "statisticalMethod": "MMRM", "paramType": "LS Mean Difference", "paramValue": "-2.32", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-5.15", "ciUpperLimit": "0.50"}, {"groupIds": ["OG000", "OG001"], "groupDescription": "Change from Baseline at Week 8", "nonInferiorityType": "SUPERIORITY", "pValue": "0.0011", "pValueComment": "MMRM method with model terms of treatment, trial site, visit, treatment-by-visit and baseline-by-visit interaction were used for analysis.", "statisticalMethod": "MMRM", "paramType": "LS Mean Difference", "paramValue": "-5.08", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-8.12", "ciUpperLimit": "-2.05"}, {"groupIds": ["OG000", "OG001"], "groupDescription": "Change from Baseline at Week 10", "nonInferiorityType": "SUPERIORITY", "pValue": "<.0001", "pValueComment": "MMRM method with model terms of treatment, trial site, visit, treatment-by-visit and baseline-by-visit interaction were used for analysis.", "statisticalMethod": "MMRM", "paramType": "LS Mean Difference", "paramValue": "-6.47", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-9.54", "ciUpperLimit": "-3.40"}, {"groupIds": ["OG000", "OG001"], "groupDescription": "Change from Baseline at Week 12", "nonInferiorityType": "SUPERIORITY", "pValue": "0.0026", "pValueComment": "MMRM method with model terms of treatment, trial site, visit, treatment-by-visit and baseline-by-visit interaction were used for analysis.", "statisticalMethod": "MMRM", "paramType": "LS Mean Difference", "paramValue": "-5.32", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-8.77", "ciUpperLimit": "-1.87"}]}, {"type": "SECONDARY", "title": "Change From Baseline in CGI-S for Each Trial Visit During the Double-Blind Treatment Period", "description": "CGI-S was used to rate the severity of agitation. The score ranges from 0 to 7 with response choices as, 0=not assessed; 1=normal, not at all ill; 2=borderline mentally ill; 3=mildly ill; 4=moderately ill; 5=markedly ill; 6=severely ill; and 7=among the most extremely ill participants. The higher the value, the more severe the agitation. A negative change from baseline indicates improvement. MMRM was used for the analysis. As prespecified in the SAP, data for this outcome measure was analyzed and reported in a combined way for brexpiprazole 2 and 3 mg.", "populationDescription": "The ITT Population consisted of all participants in the randomized sample, who took at least 1 dose of IMP and had a baseline and at least one post-baseline evaluation for the CMAI total score. Overall number analyzed is the number of participants with data available for analyses.", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "score on a scale", "timeFrame": "Baseline, Weeks 2, 4, 6, 8, 10, and 12", "groups": [{"id": "OG000", "title": "Brexpiprazole 2 and 3 mg", "description": "Participants followed a titration schedule, to gradually increase their dose from 0.5 mg/day in the starting to 2 mg/day from Day 15 or from 0.5 mg/day in the starting to 3 mg/day from Day 29.\n\nParticipants continued to receive brexpiprazole 2 or 3 mg, once daily until Week 12."}, {"id": "OG001", "title": "Placebo", "description": "Participants received matching placebo, once daily for 12 weeks."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "225"}, {"groupId": "OG001", "value": "116"}]}], "classes": [{"title": "Change From Baseline at Week 2", "categories": [{"measurements": [{"groupId": "OG000", "value": "-0.21", "spread": "0.03"}, {"groupId": "OG001", "value": "-0.27", "spread": "0.04"}]}]}, {"title": "Change From Baseline at Week 4", "categories": [{"measurements": [{"groupId": "OG000", "value": "-0.53", "spread": "0.05"}, {"groupId": "OG001", "value": "-0.50", "spread": "0.06"}]}]}, {"title": "Change From Baseline at Week 6", "categories": [{"measurements": [{"groupId": "OG000", "value": "-0.74", "spread": "0.05"}, {"groupId": "OG001", "value": "-0.68", "spread": "0.07"}]}]}, {"title": "Change From Baseline at Week 8", "categories": [{"measurements": [{"groupId": "OG000", "value": "-0.97", "spread": "0.06"}, {"groupId": "OG001", "value": "-0.70", "spread": "0.08"}]}]}, {"title": "Change From Baseline at Week 10", "categories": [{"measurements": [{"groupId": "OG000", "value": "-1.14", "spread": "0.06"}, {"groupId": "OG001", "value": "-0.86", "spread": "0.08"}]}]}, {"title": "Change From Baseline at Week 12", "categories": [{"measurements": [{"groupId": "OG000", "value": "-1.20", "spread": "0.06"}, {"groupId": "OG001", "value": "-0.93", "spread": "0.08"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "groupDescription": "Change from Baseline at Week 2", "nonInferiorityType": "SUPERIORITY", "pValue": "0.3048", "pValueComment": "MMRM method with model terms of treatment, trial site, visit, treatment-by-visit and baseline-by-visit interaction were used for analysis.", "statisticalMethod": "MMRM", "paramType": "LS Mean Difference", "paramValue": "0.05", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-0.05", "ciUpperLimit": "0.16"}, {"groupIds": ["OG000", "OG001"], "groupDescription": "Change from Baseline at Week 4", "nonInferiorityType": "SUPERIORITY", "pValue": "0.7058", "pValueComment": "MMRM method with model terms of treatment, trial site, visit, treatment-by-visit and baseline-by-visit interaction were used for analysis.", "statisticalMethod": "MMRM", "paramType": "LS Mean Difference", "paramValue": "-0.03", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-0.17", "ciUpperLimit": "0.12"}, {"groupIds": ["OG000", "OG001"], "groupDescription": "Change from Baseline at Week 6", "nonInferiorityType": "SUPERIORITY", "pValue": "0.4516", "pValueComment": "MMRM method with model terms of treatment, trial site, visit, treatment-by-visit and baseline-by-visit interaction were used for analysis.", "statisticalMethod": "MMRM", "paramType": "LS Mean Difference", "paramValue": "-0.06", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-0.23", "ciUpperLimit": "0.10"}, {"groupIds": ["OG000", "OG001"], "groupDescription": "Change from Baseline at Week 8", "nonInferiorityType": "SUPERIORITY", "pValue": "0.0052", "pValueComment": "MMRM method with model terms of treatment, trial site, visit, treatment-by-visit and baseline-by-visit interaction were used for analysis.", "statisticalMethod": "MMRM", "paramType": "LS Mean Difference", "paramValue": "-0.27", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-0.46", "ciUpperLimit": "-0.08"}, {"groupIds": ["OG000", "OG001"], "groupDescription": "Change from Baseline at Week 10", "nonInferiorityType": "SUPERIORITY", "pValue": "0.0060", "pValueComment": "MMRM method with model terms of treatment, trial site, visit, treatment-by-visit and baseline-by-visit interaction were used for analysis.", "statisticalMethod": "MMRM", "paramType": "LS Mean Difference", "paramValue": "-0.27", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-0.47", "ciUpperLimit": "-0.08"}, {"groupIds": ["OG000", "OG001"], "groupDescription": "Change from Baseline at Week 12", "nonInferiorityType": "SUPERIORITY", "pValue": "0.0078", "pValueComment": "MMRM method with model terms of treatment, trial site, visit, treatment-by-visit and baseline-by-visit interaction were used for analysis.", "statisticalMethod": "MMRM", "paramType": "LS Mean Difference", "paramValue": "-0.27", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-0.47", "ciUpperLimit": "-0.07"}]}, {"type": "SECONDARY", "title": "Clinical Global Impressions-Improvement (CGI-I) Score at Each Trial Visit During the Double-Blind Treatment Period", "description": "CGI-I is a 7-point scale that requires the clinician to assess whether a participant's condition has improved or worsened relative to a baseline state at the beginning of the intervention. This was rated as: 1=very much improved; 2=much improved; 3=minimally improved; 4=no change; 5=minimally worse; 6=much worse; or 7=very much worse. Higher scores indicate worse condition. As prespecified in the SAP, data for this outcome measure was analyzed and reported in a combined way for brexpiprazole 2 and 3 mg.", "populationDescription": "The ITT Population consisted of all participants in the randomized sample, who took at least 1 dose of IMP and had a baseline and at least one post-baseline evaluation for the CMAI total score. Overall number analyzed is the number of participants with data available for analyses. Number analyzed is the number of participants with data available for analysis at the specified time point.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "score on a scale", "timeFrame": "Baseline, Weeks 2, 4, 6, 8, 10, and 12", "groups": [{"id": "OG000", "title": "Brexpiprazole 2 and 3 mg", "description": "Participants followed a titration schedule, to gradually increase their dose from 0.5 mg/day in the starting to 2 mg/day from Day 15 or from 0.5 mg/day in the starting to 3 mg/day from Day 29.\n\nParticipants continued to receive brexpiprazole 2 or 3 mg, once daily until Week 12."}, {"id": "OG001", "title": "Placebo", "description": "Participants received matching placebo, once daily for 12 weeks."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "225"}, {"groupId": "OG001", "value": "116"}]}], "classes": [{"title": "Week 2", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "221"}, {"groupId": "OG001", "value": "114"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "3.70", "spread": "0.75"}, {"groupId": "OG001", "value": "3.57", "spread": "0.69"}]}]}, {"title": "Week 4", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "225"}, {"groupId": "OG001", "value": "116"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "3.19", "spread": "0.85"}, {"groupId": "OG001", "value": "3.39", "spread": "0.87"}]}]}, {"title": "Week 6", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "225"}, {"groupId": "OG001", "value": "116"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "2.92", "spread": "0.94"}, {"groupId": "OG001", "value": "3.19", "spread": "0.95"}]}]}, {"title": "Week 8", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "225"}, {"groupId": "OG001", "value": "116"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "2.80", "spread": "1.00"}, {"groupId": "OG001", "value": "3.16", "spread": "1.01"}]}]}, {"title": "Week 10", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "225"}, {"groupId": "OG001", "value": "116"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "2.62", "spread": "0.99"}, {"groupId": "OG001", "value": "2.97", "spread": "1.00"}]}]}, {"title": "Week 12", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "225"}, {"groupId": "OG001", "value": "116"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "2.66", "spread": "1.09"}, {"groupId": "OG001", "value": "2.97", "spread": "1.12"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "groupDescription": "Week 2", "nonInferiorityType": "SUPERIORITY", "pValue": "0.1975", "statisticalMethod": "Cochran-Mantel-Haenszel", "paramType": "Mean Difference (Final Values)", "paramValue": "0.10", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-0.05", "ciUpperLimit": "0.26"}, {"groupIds": ["OG000", "OG001"], "groupDescription": "Week 4", "nonInferiorityType": "SUPERIORITY", "pValue": "0.0084", "statisticalMethod": "Cochran-Mantel-Haenszel", "paramType": "Mean Difference (Final Values)", "paramValue": "-0.25", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-0.44", "ciUpperLimit": "-0.06"}, {"groupIds": ["OG000", "OG001"], "groupDescription": "Week 6", "nonInferiorityType": "SUPERIORITY", "pValue": "0.0101", "statisticalMethod": "Cochran-Mantel-Haenszel", "paramType": "Mean Difference (Final Values)", "paramValue": "-0.26", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-0.46", "ciUpperLimit": "-0.06"}, {"groupIds": ["OG000", "OG001"], "groupDescription": "Week 8", "nonInferiorityType": "SUPERIORITY", "pValue": "0.0008", "statisticalMethod": "Cochran-Mantel-Haenszel", "paramType": "Mean Difference (Final Values)", "paramValue": "-0.37", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-0.59", "ciUpperLimit": "-0.15"}, {"groupIds": ["OG000", "OG001"], "groupDescription": "Week 10", "nonInferiorityType": "SUPERIORITY", "pValue": "0.0023", "statisticalMethod": "Cochran-Mantel-Haenszel", "paramType": "Mean Difference (Final Values)", "paramValue": "-0.34", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-0.55", "ciUpperLimit": "-0.12"}, {"groupIds": ["OG000", "OG001"], "groupDescription": "Week 12", "nonInferiorityType": "SUPERIORITY", "pValue": "0.0070", "statisticalMethod": "Cochran-Mantel-Haenszel", "paramType": "Mean Difference (Final Values)", "paramValue": "-0.33", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-0.57", "ciUpperLimit": "-0.09"}]}, {"type": "SECONDARY", "title": "CMAI Response Rate Assessed as Percentage of Participants With CMAI Response at Every Scheduled Trial Visit in the Double-Blind Treatment Period", "description": "The CMAI assesses frequency of agitated behaviors in elderly persons. The scale consists of 29 agitated behaviors that are further categorized into distinct agitation syndromes, also known as CMAI factors of agitation. Each of the agitated behaviors are scored 1 (never) to 7 (several times an hours), with the total scale score ranging from 29 to 203. Higher score indicates greater frequency of agitated behavior. As prespecified in the SAP, data for this outcome measure was analyzed and reported in a combined way for brexpiprazole 2 and 3 mg.", "populationDescription": "The ITT Population consisted of all participants in the randomized sample, who took at least 1 dose of IMP and had a baseline and at least one post-baseline evaluation for the CMAI total score. Overall number analyzed is the number of participants with data available for analyses. Number analyzed is the number of participants with data available for analysis at the specified time point.", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "percentage of participants", "timeFrame": "Weeks 2, 4, 6, 8, 10, and 12", "groups": [{"id": "OG000", "title": "Brexpiprazole 2 and 3 mg", "description": "Participants followed a titration schedule, to gradually increase their dose from 0.5 mg/day in the starting to 2 mg/day from Day 15 or from 0.5 mg/day in the starting to 3 mg/day from Day 29.\n\nParticipants continued to receive brexpiprazole 2 or 3 mg, once daily until Week 12."}, {"id": "OG001", "title": "Placebo", "description": "Participants received matching placebo, once daily for 12 weeks."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "225"}, {"groupId": "OG001", "value": "116"}]}], "classes": [{"title": ">/= 20%: Week 2", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "221"}, {"groupId": "OG001", "value": "114"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "11.3"}, {"groupId": "OG001", "value": "13.2"}]}]}, {"title": ">/= 20%: Week 4", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "225"}, {"groupId": "OG001", "value": "116"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "29.3"}, {"groupId": "OG001", "value": "27.6"}]}]}, {"title": ">/= 20%: Week 6", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "225"}, {"groupId": "OG001", "value": "116"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "43.1"}, {"groupId": "OG001", "value": "37.9"}]}]}, {"title": ">/= 20%: Week 8", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "225"}, {"groupId": "OG001", "value": "116"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "59.6"}, {"groupId": "OG001", "value": "38.8"}]}]}, {"title": ">/= 20%: Week 10", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "225"}, {"groupId": "OG001", "value": "116"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "65.8"}, {"groupId": "OG001", "value": "45.7"}]}]}, {"title": ">/= 20%: Week 12", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "225"}, {"groupId": "OG001", "value": "116"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "68.4"}, {"groupId": "OG001", "value": "47.4"}]}]}, {"title": ">/= 30%: Week 2", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "221"}, {"groupId": "OG001", "value": "114"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "3.62"}, {"groupId": "OG001", "value": "3.51"}]}]}, {"title": ">/= 30%: Week 4", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "225"}, {"groupId": "OG001", "value": "116"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "10.7"}, {"groupId": "OG001", "value": "10.3"}]}]}, {"title": ">/= 30%: Week 6", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "225"}, {"groupId": "OG001", "value": "116"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "22.7"}, {"groupId": "OG001", "value": "20.7"}]}]}, {"title": ">/= 30%: Week 8", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "225"}, {"groupId": "OG001", "value": "116"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "32.9"}, {"groupId": "OG001", "value": "19.0"}]}]}, {"title": ">/= 30%: Week 10", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "225"}, {"groupId": "OG001", "value": "116"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "38.2"}, {"groupId": "OG001", "value": "24.1"}]}]}, {"title": ">/= 30%: Week 12", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "225"}, {"groupId": "OG001", "value": "116"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "42.7"}, {"groupId": "OG001", "value": "25.9"}]}]}, {"title": ">/= 40%: Week 2", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "221"}, {"groupId": "OG001", "value": "114"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "1.81"}, {"groupId": "OG001", "value": "1.75"}]}]}, {"title": ">/= 40%: Week 4", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "225"}, {"groupId": "OG001", "value": "116"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "4.89"}, {"groupId": "OG001", "value": "5.17"}]}]}, {"title": ">/= 40%: Week 6", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "225"}, {"groupId": "OG001", "value": "116"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "10.7"}, {"groupId": "OG001", "value": "8.62"}]}]}, {"title": ">/= 40%: Week 8", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "225"}, {"groupId": "OG001", "value": "116"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "16.9"}, {"groupId": "OG001", "value": "8.62"}]}]}, {"title": ">/= 40%: Week 10", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "225"}, {"groupId": "OG001", "value": "116"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "20.9"}, {"groupId": "OG001", "value": "11.2"}]}]}, {"title": ">/= 40%: Week 12", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "225"}, {"groupId": "OG001", "value": "116"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "23.1"}, {"groupId": "OG001", "value": "14.7"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "groupDescription": "\\>/= 20%: Week 2", "nonInferiorityType": "SUPERIORITY", "pValue": "0.7290", "statisticalMethod": "Cochran-Mantel-Haenszel", "paramType": "Ratio of Response Rate", "paramValue": "1.10", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "0.64", "ciUpperLimit": "1.91"}, {"groupIds": ["OG000", "OG001"], "groupDescription": "\\>/=20%: Week 4", "nonInferiorityType": "SUPERIORITY", "pValue": "0.6196", "statisticalMethod": "Cochran-Mantel-Haenszel", "paramType": "Ratio of Response Rate", "paramValue": "1.09", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "0.78", "ciUpperLimit": "1.52"}, {"groupIds": ["OG000", "OG001"], "groupDescription": "\\>/=20%: Week 6", "nonInferiorityType": "SUPERIORITY", "pValue": "0.2718", "statisticalMethod": "Cochran-Mantel-Haenszel", "paramType": "Ratio of Response Rate", "paramValue": "1.16", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "0.88", "ciUpperLimit": "1.53"}, {"groupIds": ["OG000", "OG001"], "groupDescription": "\\>/=20%: Week 8", "nonInferiorityType": "SUPERIORITY", "pValue": "0.0004", "statisticalMethod": "Cochran-Mantel-Haenszel", "paramType": "Ratio of Response Rate", "paramValue": "1.52", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "1.19", "ciUpperLimit": "1.93"}, {"groupIds": ["OG000", "OG001"], "groupDescription": "\\>/=20%: Week 10", "nonInferiorityType": "SUPERIORITY", "pValue": "0.0006", "statisticalMethod": "Cochran-Mantel-Haenszel", "paramType": "Ratio of Response Rate", "paramValue": "1.42", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "1.15", "ciUpperLimit": "1.76"}, {"groupIds": ["OG000", "OG001"], "groupDescription": "\\>/=20%: Week 12", "nonInferiorityType": "SUPERIORITY", "pValue": "0.0004", "statisticalMethod": "Cochran-Mantel-Haenszel", "paramType": "Ratio of Response Rate", "paramValue": "1.41", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "1.15", "ciUpperLimit": "1.72"}, {"groupIds": ["OG000", "OG001"], "groupDescription": "\\>/=30%: Week 2", "nonInferiorityType": "SUPERIORITY", "pValue": "0.7211", "statisticalMethod": "Cochran-Mantel-Haenszel", "paramType": "Ratio of Response Rate", "paramValue": "1.22", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "0.39", "ciUpperLimit": "3.85"}, {"groupIds": ["OG000", "OG001"], "groupDescription": "\\>/=30%: Week 4", "nonInferiorityType": "SUPERIORITY", "pValue": "0.7606", "statisticalMethod": "Cochran-Mantel-Haenszel", "paramType": "Ratio of Response Rate", "paramValue": "1.11", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "0.57", "ciUpperLimit": "2.14"}, {"groupIds": ["OG000", "OG001"], "groupDescription": "\\>/=30%: Week 6", "nonInferiorityType": "SUPERIORITY", "pValue": "0.5902", "statisticalMethod": "Cochran-Mantel-Haenszel", "paramType": "Ratio of Response Rate", "paramValue": "1.12", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "0.74", "ciUpperLimit": "1.68"}, {"groupIds": ["OG000", "OG001"], "groupDescription": "\\>/=30%: Week 8", "nonInferiorityType": "SUPERIORITY", "pValue": "0.0054", "statisticalMethod": "Cochran-Mantel-Haenszel", "paramType": "Ratio of Response Rate", "paramValue": "1.70", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "1.14", "ciUpperLimit": "2.54"}, {"groupIds": ["OG000", "OG001"], "groupDescription": "\\>/=30%: Week 10", "nonInferiorityType": "SUPERIORITY", "pValue": "0.0066", "statisticalMethod": "Cochran-Mantel-Haenszel", "paramType": "Ratio of Response Rate", "paramValue": "1.59", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "1.11", "ciUpperLimit": "2.26"}, {"groupIds": ["OG000", "OG001"], "groupDescription": "\\>/=30%: Week 12", "nonInferiorityType": "SUPERIORITY", "pValue": "0.0017", "statisticalMethod": "Cochran-Mantel-Haenszel", "paramType": "Ratio of Response Rate", "paramValue": "1.62", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "1.18", "ciUpperLimit": "2.23"}, {"groupIds": ["OG000", "OG001"], "groupDescription": "\\>/=40%: Week 2", "nonInferiorityType": "SUPERIORITY", "pValue": "0.9074", "statisticalMethod": "Cochran-Mantel-Haenszel", "paramType": "Ratio of Response Rate", "paramValue": "1.11", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "0.20", "ciUpperLimit": "5.97"}, {"groupIds": ["OG000", "OG001"], "groupDescription": "\\>/=40%: Week 4", "nonInferiorityType": "SUPERIORITY", "pValue": "0.9625", "statisticalMethod": "Cochran-Mantel-Haenszel", "paramType": "Ratio of Response Rate", "paramValue": "0.98", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "0.36", "ciUpperLimit": "2.64"}, {"groupIds": ["OG000", "OG001"], "groupDescription": "\\>/=40%: Week 6", "nonInferiorityType": "SUPERIORITY", "pValue": "0.5120", "statisticalMethod": "Cochran-Mantel-Haenszel", "paramType": "Ratio of Response Rate", "paramValue": "1.26", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "0.63", "ciUpperLimit": "2.53"}, {"groupIds": ["OG000", "OG001"], "groupDescription": "\\>/=40%: Week 8", "nonInferiorityType": "SUPERIORITY", "pValue": "0.0244", "statisticalMethod": "Cochran-Mantel-Haenszel", "paramType": "Ratio of Response Rate", "paramValue": "1.98", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "1.03", "ciUpperLimit": "3.79"}, {"groupIds": ["OG000", "OG001"], "groupDescription": "\\>/=40%: Week 10", "nonInferiorityType": "SUPERIORITY", "pValue": "0.0161", "statisticalMethod": "Cochran-Mantel-Haenszel", "paramType": "Ratio of Response Rate", "paramValue": "1.86", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "1.08", "ciUpperLimit": "3.18"}, {"groupIds": ["OG000", "OG001"], "groupDescription": "\\>/=40%: Week 12", "nonInferiorityType": "SUPERIORITY", "pValue": "0.0347", "statisticalMethod": "Cochran-Mantel-Haenszel", "paramType": "Ratio of Response Rate", "paramValue": "1.62", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "1.00", "ciUpperLimit": "2.61"}]}, {"type": "SECONDARY", "title": "CMAI Response Rate Assessed as Percentage of Participants With CMAI Response Based on Improvement From Baseline in Agitation Status at Every Scheduled Trial Visit in the Double-Blind Treatment Period", "description": "The CMAI assesses frequency of agitated behaviors in elderly persons. The scale consists of 29 agitated behaviors that are further categorized into distinct agitation syndromes, also known as CMAI factors of agitation. Each of the agitated behaviors are scored 1 (never) to 7 (several times an hours), with the total scale score ranging from 29 to 203. Higher score indicates greater frequency of agitated behavior. As prespecified in the SAP, data for this outcome measure was analyzed and reported in a combined way for brexpiprazole 2 and 3 mg.", "populationDescription": "The ITT Population consisted of all participants in the randomized sample, who took at least 1 dose of IMP and had a baseline and at least one post-baseline evaluation for the CMAI total score. Overall number analyzed is the number of participants with data available for analyses. Number analyzed is the number of participants with data available for analysis at the specified time point.", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "percentage of participants", "timeFrame": "Baseline, Weeks 2, 4, 6, 8, 10, and 12", "groups": [{"id": "OG000", "title": "Brexpiprazole 2 and 3 mg", "description": "Participants followed a titration schedule, to gradually increase their dose from 0.5 mg/day in the starting to 2 mg/day from Day 15 or from 0.5 mg/day in the starting to 3 mg/day from Day 29.\n\nParticipants continued to receive brexpiprazole 2 or 3 mg, once daily until Week 12."}, {"id": "OG001", "title": "Placebo", "description": "Participants received matching placebo, once daily for 12 weeks."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "225"}, {"groupId": "OG001", "value": "116"}]}], "classes": [{"title": "Week 2", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "221"}, {"groupId": "OG001", "value": "114"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "8.14"}, {"groupId": "OG001", "value": "14.0"}]}]}, {"title": "Week 4", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "225"}, {"groupId": "OG001", "value": "116"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "20.4"}, {"groupId": "OG001", "value": "19.0"}]}]}, {"title": "Week 6", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "225"}, {"groupId": "OG001", "value": "116"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "33.8"}, {"groupId": "OG001", "value": "26.7"}]}]}, {"title": "Week 8", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "225"}, {"groupId": "OG001", "value": "116"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "44.0"}, {"groupId": "OG001", "value": "31.0"}]}]}, {"title": "Week 10", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "225"}, {"groupId": "OG001", "value": "116"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "50.2"}, {"groupId": "OG001", "value": "34.5"}]}]}, {"title": "Week 12", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "225"}, {"groupId": "OG001", "value": "116"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "52.4"}, {"groupId": "OG001", "value": "37.1"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "groupDescription": "Week 2", "nonInferiorityType": "SUPERIORITY", "pValue": "0.1503", "statisticalMethod": "Cochran-Mantel-Haenszel", "paramType": "Ratio of Response Rate", "paramValue": "0.64", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "0.35", "ciUpperLimit": "1.16"}, {"groupIds": ["OG000", "OG001"], "groupDescription": "Week 4", "nonInferiorityType": "SUPERIORITY", "pValue": "0.7559", "statisticalMethod": "Cochran-Mantel-Haenszel", "paramType": "Ratio of Response Rate", "paramValue": "1.07", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "0.69", "ciUpperLimit": "1.67"}, {"groupIds": ["OG000", "OG001"], "groupDescription": "Week 6", "nonInferiorityType": "SUPERIORITY", "pValue": "0.2246", "statisticalMethod": "Cochran-Mantel-Haenszel", "paramType": "Ratio of Response Rate", "paramValue": "1.23", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "0.88", "ciUpperLimit": "1.72"}, {"groupIds": ["OG000", "OG001"], "groupDescription": "Week 8", "nonInferiorityType": "SUPERIORITY", "pValue": "0.0276", "statisticalMethod": "Cochran-Mantel-Haenszel", "paramType": "Ratio of Response Rate", "paramValue": "1.38", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "1.02", "ciUpperLimit": "1.87"}, {"groupIds": ["OG000", "OG001"], "groupDescription": "Week 10", "nonInferiorityType": "SUPERIORITY", "pValue": "0.0031", "statisticalMethod": "Cochran-Mantel-Haenszel", "paramType": "Ratio of Response Rate", "paramValue": "1.46", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "1.12", "ciUpperLimit": "1.89"}, {"groupIds": ["OG000", "OG001"], "groupDescription": "Week 12", "nonInferiorityType": "SUPERIORITY", "pValue": "0.0017", "statisticalMethod": "Cochran-Mantel-Haenszel", "paramType": "Ratio of Response Rate", "paramValue": "1.47", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "1.14", "ciUpperLimit": "1.89"}]}, {"type": "SECONDARY", "title": "CGI-I Response Rate Assessed as Percentage of Participants With CGI-I Response at Every Scheduled Trial Visit in the Double-Blind Treatment Period", "description": "CGI-I is a 7-point scale that requires the clinician to assess whether a participant's condition has improved or worsened relative to a baseline state at the beginning of the intervention. This was rated as: 1=very much improved; 2=much improved; 3=minimally improved; 4=no change; 5=minimally worse; 6=much worse; or 7=very much worse. Higher scores indicate worse condition. As prespecified in the SAP, data for this outcome measure was analyzed and reported in a combined way for brexpiprazole 2 and 3 mg.", "populationDescription": "The ITT Population consisted of all participants in the randomized sample, who took at least 1 dose of IMP and had a baseline and at least one post-baseline evaluation for the CMAI total score. Overall number analyzed is the number of participants with data available for analyses. Number analyzed is the number of participants with data available for analysis at the specified time point.", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "percentage of participants", "timeFrame": "Baseline, Weeks 2, 4, 6, 8, 10, and 12", "groups": [{"id": "OG000", "title": "Brexpiprazole 2 and 3 mg", "description": "Participants followed a titration schedule, to gradually increase their dose from 0.5 mg/day in the starting to 2 mg/day from Day 15 or from 0.5 mg/day in the starting to 3 mg/day from Day 29.\n\nParticipants continued to receive brexpiprazole 2 or 3 mg, once daily until Week 12."}, {"id": "OG001", "title": "Placebo", "description": "Participants received matching placebo, once daily for 12 weeks."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "225"}, {"groupId": "OG001", "value": "116"}]}], "classes": [{"title": "Week 2", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "221"}, {"groupId": "OG001", "value": "114"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "4.98"}, {"groupId": "OG001", "value": "5.26"}]}]}, {"title": "Week 4", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "225"}, {"groupId": "OG001", "value": "116"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "21.8"}, {"groupId": "OG001", "value": "12.1"}]}]}, {"title": "Week 6", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "225"}, {"groupId": "OG001", "value": "116"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "35.1"}, {"groupId": "OG001", "value": "23.3"}]}]}, {"title": "Week 8", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "225"}, {"groupId": "OG001", "value": "116"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "44.4"}, {"groupId": "OG001", "value": "24.1"}]}]}, {"title": "Week 10", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "225"}, {"groupId": "OG001", "value": "116"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "52.4"}, {"groupId": "OG001", "value": "33.6"}]}]}, {"title": "Week 12", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "225"}, {"groupId": "OG001", "value": "116"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "52.4"}, {"groupId": "OG001", "value": "40.5"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "groupDescription": "Week 2", "nonInferiorityType": "SUPERIORITY", "pValue": "0.8549", "statisticalMethod": "Cochran-Mantel-Haenszel", "paramType": "Ratio of Response Rate", "paramValue": "1.10", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "0.40", "ciUpperLimit": "3.03"}, {"groupIds": ["OG000", "OG001"], "groupDescription": "Week 4", "nonInferiorityType": "SUPERIORITY", "pValue": "0.0093", "statisticalMethod": "Cochran-Mantel-Haenszel", "paramType": "Ratio of Response Rate", "paramValue": "1.95", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "1.14", "ciUpperLimit": "3.32"}, {"groupIds": ["OG000", "OG001"], "groupDescription": "Week 6", "nonInferiorityType": "SUPERIORITY", "pValue": "0.0083", "statisticalMethod": "Cochran-Mantel-Haenszel", "paramType": "Ratio of Response Rate", "paramValue": "1.56", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "1.10", "ciUpperLimit": "2.22"}, {"groupIds": ["OG000", "OG001"], "groupDescription": "Week 8", "nonInferiorityType": "SUPERIORITY", "pValue": "<.0001", "statisticalMethod": "Cochran-Mantel-Haenszel", "paramType": "Ratio of Response Rate", "paramValue": "1.85", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "1.32", "ciUpperLimit": "2.58"}, {"groupIds": ["OG000", "OG001"], "groupDescription": "Week 10", "nonInferiorityType": "SUPERIORITY", "pValue": "0.0005", "statisticalMethod": "Cochran-Mantel-Haenszel", "paramType": "Ratio of Response Rate", "paramValue": "1.57", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "1.18", "ciUpperLimit": "2.09"}, {"groupIds": ["OG000", "OG001"], "groupDescription": "Week 12", "nonInferiorityType": "SUPERIORITY", "pValue": "0.0160", "statisticalMethod": "Cochran-Mantel-Haenszel", "paramType": "Ratio of Response Rate", "paramValue": "1.32", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "1.03", "ciUpperLimit": "1.69"}]}]}, "adverseEventsModule": {"frequencyThreshold": "5", "timeFrame": "From signing of informed consent up to end of study (Week 16)", "description": "Randomized Sample was used to assess all-cause mortality. It consisted of all participants who were randomized into this trial. Safety Sample was used to assess serious adverse events (SAEs) and other adverse events (AEs) and consisted of all participants who were administered at least one dose of IMP.", "eventGroups": [{"id": "EG000", "title": "Brexpiprazole 2 mg", "description": "Participants followed a titration schedule, to gradually increase their dose from 0.5 mg/day in the starting to 2 mg/day from Day 15. Participants continued to receive brexpiprazole 2 mg, once daily until Week 12.", "deathsNumAffected": 0, "deathsNumAtRisk": 75, "seriousNumAffected": 0, "seriousNumAtRisk": 73, "otherNumAffected": 5, "otherNumAtRisk": 73}, {"id": "EG001", "title": "Brexpiprazole 3 mg", "description": "Participants followed a titration schedule, to gradually increase their dose from 0.5 mg/day in the starting to 3 mg/day from Day 29. Participants continued to receive brexpiprazole 3 mg, once daily until Week 12.", "deathsNumAffected": 1, "deathsNumAtRisk": 153, "seriousNumAffected": 6, "seriousNumAtRisk": 153, "otherNumAffected": 10, "otherNumAtRisk": 153}, {"id": "EG002", "title": "Placebo", "description": "Participants received matching placebo, once daily for 12 weeks.", "deathsNumAffected": 0, "deathsNumAtRisk": 117, "seriousNumAffected": 3, "seriousNumAtRisk": 116, "otherNumAffected": 8, "otherNumAtRisk": 116}], "seriousEvents": [{"term": "Cardiac failure", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA (25.1)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 73}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 153}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 116}]}, {"term": "Covid-19", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA (25.1)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 73}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 153}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 116}]}, {"term": "Pneumonia", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA (25.1)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 73}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 153}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 116}]}, {"term": "Urinary tract infection", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA (25.1)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 73}, {"groupId": "EG001", "numAffected": 2, "numAtRisk": 153}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 116}]}, {"term": "Fall", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA (25.1)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 73}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 153}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 116}]}, {"term": "Hip fracture", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA (25.1)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 73}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 153}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 116}]}, {"term": "Sars-Cov-2 test positive", "organSystem": "Investigations", "sourceVocabulary": "MedDRA (25.1)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 73}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 153}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 116}]}, {"term": "Cachexia", "organSystem": "Metabolism and nutrition disorders", "sourceVocabulary": "MedDRA (25.1)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 73}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 153}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 116}]}, {"term": "Dehydration", "organSystem": "Metabolism and nutrition disorders", "sourceVocabulary": "MedDRA (25.1)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 73}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 153}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 116}]}, {"term": "Metabolic acidosis", "organSystem": "Metabolism and nutrition disorders", "sourceVocabulary": "MedDRA (25.1)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 73}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 153}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 116}]}, {"term": "Mental status change", "organSystem": "Psychiatric disorders", "sourceVocabulary": "MedDRA (25.1)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 73}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 153}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 116}]}, {"term": "Psychotic disorder", "organSystem": "Psychiatric disorders", "sourceVocabulary": "MedDRA (25.1)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 73}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 153}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 116}]}, {"term": "Acute kidney injury", "organSystem": "Renal and urinary disorders", "sourceVocabulary": "MedDRA (25.1)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 73}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 153}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 116}]}, {"term": "Hypertension", "organSystem": "Vascular disorders", "sourceVocabulary": "MedDRA (25.1)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 73}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 153}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 116}]}], "otherEvents": [{"term": "Headache", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA (25.1)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 5, "numAtRisk": 73}, {"groupId": "EG001", "numAffected": 10, "numAtRisk": 153}, {"groupId": "EG002", "numAffected": 8, "numAtRisk": 116}]}]}, "moreInfoModule": {"certainAgreement": {"piSponsorEmployee": false, "restrictionType": "OTHER", "restrictiveAgreement": true, "otherDetails": "Sponsor reserves the right to review results publications prior to public release and can delay such publications for a period greater than 60 days but no more than 120 days from the date that the publication is submitted to the Sponsor for review. Sponsor can require changes to the publication to protect Sponsor's intellectual property rights and/or confidential information and reserves the right to limit publication timing and scope of data published based on the number of study locations."}, "pointOfContact": {"title": "Director of Clinical Trials", "organization": "Otsuka Pharmaceutical Co., LTD.", "email": "CL_OPCJ_RDA_Team@otsuka.jp", "phone": "+81-3-6361-7366"}}}, "documentSection": {"largeDocumentModule": {"largeDocs": [{"typeAbbrev": "Prot", "hasProtocol": true, "hasSap": false, "hasIcf": false, "label": "Study Protocol", "date": "2020-09-15", "uploadDate": "2023-05-30T23:56", "filename": "Prot_000.pdf", "size": 3917632}, {"typeAbbrev": "SAP", "hasProtocol": false, "hasSap": true, "hasIcf": false, "label": "Statistical Analysis Plan", "date": "2022-05-31", "uploadDate": "2023-05-31T00:02", "filename": "SAP_001.pdf", "size": 7644064}]}}, "derivedSection": {"miscInfoModule": {"versionHolder": "2024-06-24", "removedCountries": ["Bulgaria", "Serbia", "Spain", "Ukraine"], "submissionTracking": {"firstMcpInfo": {"postDateStruct": {"date": "2023-06-26", "type": "ACTUAL"}}}}, "conditionBrowseModule": {"meshes": [{"id": "D000003704", "term": "Dementia"}, {"id": "D000000544", "term": "Alzheimer Disease"}, {"id": "D000011595", "term": "Psychomotor Agitation"}], "ancestors": [{"id": "D000001927", "term": "Brain Diseases"}, {"id": "D000002493", "term": "Central Nervous System Diseases"}, {"id": "D000009422", "term": "Nervous System Diseases"}, {"id": "D000019965", "term": "Neurocognitive Disorders"}, {"id": "D000001523", "term": "Mental Disorders"}, {"id": "D000024801", "term": "Tauopathies"}, {"id": "D000019636", "term": "Neurodegenerative Diseases"}, {"id": "D000020820", "term": "Dyskinesias"}, {"id": "D000009461", "term": "Neurologic Manifestations"}, {"id": "D000011596", "term": "Psychomotor Disorders"}, {"id": "D000019954", "term": "Neurobehavioral Manifestations"}, {"id": "D000096762", "term": "Aberrant Motor Behavior in Dementia"}, {"id": "D000001526", "term": "Behavioral Symptoms"}], "browseLeaves": [{"id": "M6904", "name": "Dementia", "asFound": "Dementia", "relevance": "HIGH"}, {"id": "M3885", "name": "Alzheimer Disease", "asFound": "Alzheimer's Dementia", "relevance": "HIGH"}, {"id": "M14452", "name": "Psychomotor Agitation", "asFound": "Agitation", "relevance": "HIGH"}, {"id": "M5204", "name": "Brain Diseases", "relevance": "LOW"}, {"id": "M5742", "name": "Central Nervous System Diseases", "relevance": "LOW"}, {"id": "M21836", "name": "Neurocognitive Disorders", "relevance": "LOW"}, {"id": "M4815", "name": "Mental Disorders", "relevance": "LOW"}, {"id": "M14473", "name": "Psychotic Disorders", "relevance": "LOW"}, {"id": "M23002", "name": "Tauopathies", "relevance": "LOW"}, {"id": "M21558", "name": "Neurodegenerative Diseases", "relevance": "LOW"}, {"id": "M22574", "name": "Dyskinesias", "relevance": "LOW"}, {"id": "M12404", "name": "Neurologic Manifestations", "relevance": "LOW"}, {"id": "M14453", "name": "Psychomotor Disorders", "relevance": "LOW"}, {"id": "M21826", "name": "Neurobehavioral Manifestations", "relevance": "LOW"}, {"id": "M3259", "name": "Aberrant Motor Behavior in Dementia", "relevance": "LOW"}, {"id": "M4818", "name": "Behavioral Symptoms", "relevance": "LOW"}, {"id": "T2192", "name": "Familial Alzheimer Disease", "asFound": "Alzheimer's Dementia", "relevance": "HIGH"}], "browseBranches": [{"abbrev": "BC10", "name": "Nervous System Diseases"}, {"abbrev": "BXM", "name": "Behaviors and Mental Disorders"}, {"abbrev": "All", "name": "All Conditions"}, {"abbrev": "BC23", "name": "Symptoms and General Pathology"}, {"abbrev": "Rare", "name": "Rare Diseases"}]}, "interventionBrowseModule": {"meshes": [{"id": "C000591922", "term": "Brexpiprazole"}], "ancestors": [{"id": "D000018490", "term": "Serotonin Agents"}, {"id": "D000018377", "term": "Neurotransmitter Agents"}, {"id": "D000045504", "term": "Molecular Mechanisms of Pharmacological Action"}, {"id": "D000045505", "term": "Physiological Effects of Drugs"}, {"id": "D000018491", "term": "Dopamine Agonists"}, {"id": "D000015259", "term": "Dopamine Agents"}], "browseLeaves": [{"id": "M293045", "name": "Brexpiprazole", "asFound": "Cytology", "relevance": "HIGH"}, {"id": "M15512", "name": "Serotonin", "relevance": "LOW"}, {"id": "M20504", "name": "Neurotransmitter Agents", "relevance": "LOW"}, {"id": "M7473", "name": "Dopamine", "relevance": "LOW"}, {"id": "M20595", "name": "Dopamine Agonists", "relevance": "LOW"}, {"id": "M17962", "name": "Dopamine Agents", "relevance": "LOW"}], "browseBranches": [{"abbrev": "All", "name": "All Drugs and Chemicals"}, {"abbrev": "CaAg", "name": "Cardiotonic Agents"}]}}, "hasResults": true}